Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Sponsor
Dong-A ST Co., Ltd.
Study ID
NCT02974504
Phase
PHASE4
Status
Completed

Conditions

  • Type2 Diabetes

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • evogliptin — DRUG
    evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
  • Linagliptin — DRUG
    linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg

Study Details

A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes

Key Dates

First listed
Nov 28, 2016
Start date
Sep 30, 2016
Status verified
Jul 2018
Primary completion
Mar 31, 2018
Completion
Mar 31, 2018

Study Design

Enrollment
207 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: evogliptin
    evogliptin 5mg qd
  • Active Comparator: linagliptin
    linagliptin 5mg qd

Primary Outcome Measure

HbA1c [ Time Frame: Change from baseline at 12 week ]

Related Studies